NCT03910660 2025-10-20
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
BioXcel Therapeutics Inc
Phase 1/2 Completed
BioXcel Therapeutics Inc
EpicentRx, Inc.
National Cancer Institute (NCI)